As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk
Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has…
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
